S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Your Money is Not Safe (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Your Money is Not Safe (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Your Money is Not Safe (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How Biden has already won 2024 (Ad)
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
Your Money is Not Safe (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
The “Perfect Storm” for Gold (Ad)
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
Free Trial
NASDAQ:PEAR

Pear Therapeutics (PEAR) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free PEAR Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
7.75 million shs
Market Capitalization
$4.17 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media
PEAR stock logo

About Pear Therapeutics Stock (NASDAQ:PEAR)

Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.

PEAR Stock News Headlines

April 18, 2024 | yahoo.com
Work on Highway 99 northbound lanes near Avenue 12 begins
April 9, 2024 | msn.com
Exclusive: AlleyCorp raises a $250 million fund, taking on external investors for the first time
April 19, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
April 5, 2024 | msn.com
FDA approves first prescription-only app for depression
April 1, 2024 | finance.yahoo.com
Acorda Therapeutics and Merz Announce Signing of "Stalking Horse" Asset Purchase Agreement
April 1, 2024 | wsj.com
Acorda Therapeutics Files for Bankruptcy Protection
March 28, 2024 | forbes.com
Virtual Clinic Pelago Is Reimagining Rehab With $58 Million In New Funding
March 19, 2024 | bizjournals.com
Girl's rare disease inspired new drug model. Now the drug trial has hit a pivotal point
April 19, 2024 | Crypto Swap Profits (Ad)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
March 15, 2024 | finance.yahoo.com
Better Therapeutics lays off staff, considers winding down business
March 14, 2024 | finance.yahoo.com
Bratu named marketing and development director for State Games
February 21, 2024 | finance.yahoo.com
Better Therapeutics wins breakthrough status for health app to treat liver disease
January 31, 2024 | finance.yahoo.com
Global Internet Addiction Disorder Market Size Is Expected To Hold a Significant Share By 2033 | CAGR of 11.45%
January 31, 2024 | finance.yahoo.com
Smart Pills Market Set to Soar Past USD 12.39 billion by 2030
January 31, 2024 | forbes.com
How Pharma Can Borrow A Page From Digital Health Investors’ Playbook
January 31, 2024 | axios.com
Cognito Therapeutics raises $35M for neuro device
January 26, 2024 | finance.yahoo.com
Healthcare bankruptcies reached five-year peak in 2023, report finds
January 11, 2024 | finance.yahoo.com
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
December 20, 2023 | finance.yahoo.com
Digital Therapeutics Global Market to Observe Stunning Growth at a CAGR of ~28% by 2028 | DelveInsight
November 11, 2023 | morningstar.com
Pear Therapeutics Inc Class A PEARQ
November 9, 2023 | finance.yahoo.com
Nox Health Appoints Frances Thorndike, Ph.D. to lead Medical & Scientific Affairs
October 27, 2023 | seekingalpha.com
PEARQ Pear Therapeutics, Inc.
October 24, 2023 | benzinga.com
Digital Therapeutics Market Is Projected to Gain $22.60 Billion By 2031, Growing at a 19.4% CAGR: Allied Market Research
October 18, 2023 | bizjournals.com
Deals of the Year: Somryst 'literally completes our portfolio,' Nox Health CEO says
October 10, 2023 | bizjournals.com
Biotech's 2023 ghosts haunt efforts to exorcise downturn
September 28, 2023 | benzinga.com
Migraine Pipeline, Clinical Trials, Emerging Therapies and FDA Approvals 2023 (Updated)
September 25, 2023 | finance.yahoo.com
Pear Therapeutics, Inc. (PEARQ)
See More Headlines
Receive PEAR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pear Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
4/18/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Health services
Sub-Industry
N/A
Current Symbol
NASDAQ:PEAR
CUSIP
N/A
CIK
1835567
Web
peartherapeutics.com
Phone
617-925-7848
Fax
N/A
Employees
300
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.22)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-75,490,000.00
Net Margins
-594.70%
Pretax Margin
-594.70%
Return on Equity
-217.85%
Return on Assets
-95.20%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.48
Quick Ratio
1.48

Sales & Book Value

Annual Sales
$12.69 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.22 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
142,739,000
Free Float
98,918,000
Market Cap
$4.17 million
Optionable
Not Optionable
Beta
0.45
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Dr. Corey M. McCann M.D. (Age 43)
    Ph.D., Founder, Pres, CEO & Director
    Comp: $702.45k
  • Mr. Christopher D. T. Guiffre J.D. (Age 55)
    M.B.A., MBA, CFO, COO, Treasurer & Assistant Sec.
    Comp: $564.37k
  • Ms. Julia M. Strandberg M.B.A. (Age 48)
    Chief Commercial Officer
    Comp: $582.43k
  • Mr. Ronan P. O'Brien J.D. (Age 50)
    Chief Compliance Officer, Gen. Counsel & Sec.
  • Ms. Meara Murphy
    Sr. Director of Corp. Communications
  • Dr. Yuri Maricich M.B.A. (Age 43)
    M.D., Chief Medical Officer & Head of Devel.
  • Mr. Chris Valosky M.B.A.
    VP of Sales
  • Ms. Katherine Jeffery M.Sc. (Age 56)
    Chief People Officer
  • Ms. Erin K. Brenner (Age 50)
    Chief Product Devel. Officer
  • Ms. Ellen E. Snow CPA (Age 50)
    CGMA, VP & Corp. Controller

Key Competitors

View All Competitors

PEAR Stock Analysis - Frequently Asked Questions

How do I buy shares of Pear Therapeutics?

Shares of PEAR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PEAR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS
Paradigm Press
Your Money is Not Safe
American Alternative
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research